Moleculin says Annamycin trial data accepted for presentation at 2026 ASH meeting
Moleculin Biotech announced that an abstract on interim results from its pivotal MB-108 Phase 2/3 trial of Annamycin has been accepted for poster presentation at the 2026 American Society of Hematology Annual Meeting, held December 12-15, 2026 in New Orleans. The data cover the first 45 randomized patients, so the results are early and preliminary, and the independent Data Monitoring Committee recommended the study continue without amendment.
Key points
- Complete remission rates were 43% and 36% in the two Annamycin arms, versus 12% in the placebo arm, among the first 45 randomized patients.
- No signs of cardiotoxicity were observed through the data cutoff; cardiac safety data will be reviewed at the second interim analysis.
- The second interim analysis is expected in early 2027.
- The poster presentation is scheduled at the ASH meeting, December 12-15, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.